CR5 Stock Overview
A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Oculis Holding AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$10.90 |
52 Week High | US$12.80 |
52 Week Low | US$8.50 |
Beta | 0.082 |
1 Month Change | -1.80% |
3 Month Change | 0.93% |
1 Year Change | -4.72% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 35.30% |
Recent News & Updates
Recent updates
Shareholder Returns
CR5 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | -0.9% | -2.3% |
1Y | -4.7% | -16.8% | 1.0% |
Return vs Industry: CR5 exceeded the German Pharmaceuticals industry which returned -16.8% over the past year.
Return vs Market: CR5 underperformed the German Market which returned 1% over the past year.
Price Volatility
CR5 volatility | |
---|---|
CR5 Average Weekly Movement | 5.0% |
Pharmaceuticals Industry Average Movement | 5.3% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: CR5 has not had significant price volatility in the past 3 months.
Volatility Over Time: CR5's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 36 | Riad Sherif | oculis.com |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Oculis Holding AG Fundamentals Summary
CR5 fundamental statistics | |
---|---|
Market cap | €460.42m |
Earnings (TTM) | -€61.61m |
Revenue (TTM) | €916.69k |
502.3x
P/S Ratio-7.5x
P/E RatioIs CR5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CR5 income statement (TTM) | |
---|---|
Revenue | CHF876.00k |
Cost of Revenue | CHF33.96m |
Gross Profit | -CHF33.08m |
Other Expenses | CHF25.80m |
Earnings | -CHF58.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.41 |
Gross Margin | -3,776.14% |
Net Profit Margin | -6,721.46% |
Debt/Equity Ratio | 0% |
How did CR5 perform over the long term?
See historical performance and comparison